GlobeNewsWire
19 Aug 2026, 03:22 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
A class action lawsuit alleges that Aardvark Therapeutics (AARD) misrepresented the safety and commercial prospects of its drug candidate, ARD-101. — Claims regarding safety issues and overstated clinical prospects for a primary drug candidate typically lead to significant devaluation of biotech firms.
-0.60The lawsuit claims that Aardvark Therapeutics made materially false or misleading statements in its February 13, 2025 IPO registration statement and throughout a class period ending May 14, 2026. — Allegations of fraud during an IPO can damage long-term investor trust and lead to substantial legal liabilities.
-0.40Which stocks this story touches
The company is facing a class action lawsuit alleging materially false and misleading statements regarding the safety and prospects of its product ARD-101.
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is the subject of a legal notice from a law firm representing purchasers of its common stock, implying potential litigation.
The company is the subject of a legal notice from a law firm representing purchasers of its Class A common stock, implying potential litigation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
4h ago
